India's Glenmark Pharma unit, AbbVie sign exclusive licensing pact
July 10 (Reuters) - India's Glenmark Pharmaceuticals GLEN.NS said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie ABBV.N have signed an exclusive licensing agreement for IGI's cancer treatment, adding to the U.S. firm's oncology portfolio.
Under the agreement, AbbVie will get exclusive rights to develop, manufacture and commercialize IGI's ISB 2001 in North America, Europe, Japan and Greater China.
ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed or refractory multiple myeloma, a type of cancer that develops in white blood cells.
AbbVie has a pipeline of more than 20 investigational assets designed to tackle difficult-to-treat cancers, according to the company website.
Subject to regulatory approvals, IGI will receive an upfront payment of $700 million and could earn up to $1.225 billion in additional milestone payments, according to the agreement.
Related Articles
The Crypto Bull Market Returns — Four Charts Show the Catalysts Behind Bitcoin’s New High
TradingKey - Despite ongoing tariff risks from the Trump administration, Bitcoin (BTC) and NVIDIA, the most valuable stock in the U.S., have both hit new highs. After months of hovering near the $100,000 mark, Bitcoin has regained momentum — driven by stablecoin regulation, Fed rate cut expectations.jpg)
What Is Stock Tokenization — and Could Tokenized Equities Replace Traditional Stocks?
Stock tokenization refers to the process of representing traditional equities as blockchain-based digital tokens. Each token corresponds to a specific number of shares — e.g., one token may represent 1 share of NVIDIA (NVDA) or 100 shares, depending on the issuer’s rules.
Investment Plays to Watch as ‘The One, Big, Beautiful Bill’ Clears Congress
With the passage of the $3.4 trillion fiscal overhaul, which sectors and ETFs are poised to benefit from tax cuts and defense spending — and which face headwinds from social program cuts?
JPMorgan Chase & Co. 2025 Second Quarter Earnings Preview
JPMorgan Chase & Co. (JPM) is scheduled to release its 2025 second quarter earnings report before the market opens on Tuesday, July 15, 2025, at 7:00 AM Eastern Time, with a subsequent earnings conference call at 8:30 AM. As one of the world’s leading financial institutions, JPMorgan’s quarterly ear
Prediction! Federal Reserve Chairman Jerome Powell's Next Move Will Be an Interest Rate Cut
The Federal Reserve must balance the risks of higher inflation with the risks of higher unemployment when making decisions on interest rates.Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »*Stock prices used were..
